The CEOs of Eli Lilly and Novo Nordisk — rivals in the GLP-1 obesity market — addressed nagging questions at the 2024 J.P. Morgan Healthcare Conference.
JPM 2024: Renewal is a common theme among pharma CEOs
Putting a difficult year in the rearview or shedding an older image were common talking points among biopharma CEOs on day one of the JPM 2024 conference.
How biotech companies are standing out during JPM Week
2023 was a bad year for deal-making. Considering the headwinds, will 2024 be better? Here are some key questions as the JPMorgan Healthcare Conference gets underway.
Walgreens to help distribute Verrica’s molluscum drug